Sustained release characteristics of rifampin-loaded microsphere formulations in nonhuman primates

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 11, Issue 4, 2004, Pages 239-246

  Quenelle, Debra C ^a   Winchester, Gary A ^b   Staas, Jay K ^b   Hoskins, Darrel E ^b   Barrow, Esther W ^c   Barrow, William W ^c  

^a University of Alabama at Birmingham   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Biocompatible; DL Lactide Co Glycolide; Microspheres; Primates; Rifampin

Indexed keywords

MICROSPHERE; POLYGLACTIN; POLYVINYL ALCOHOL; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; FEMALE; LUNG; MACACA; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARTICLE SIZE; PRIMATE; PRIORITY JOURNAL; SPLEEN; SUSTAINED RELEASE FORMULATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; FEMALE; MACACA FASCICULARIS; MALE; MICROSPHERES; RIFAMPIN;

EID: 4143062914     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/10717540490467366     Document Type: Article

References (19)

1. Acocella, G., Nonis, A., Perna, G., Patane, E., Gialdroni-Grassi, G., and Grassi, C. 1988. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study. Am. Rev Respir. Dis. 138:886-890.
2. Barrow, E. L. W., Winchester, G. A., Staas, J. K., Quenelle, D. C., and Barrow, W. W. 1998. Use of microsphere technology for sustained and targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 42:2682-2689.
3. Berg, J. D., Ruddock, S., Allen-Narker, R. A., Bradby, G. V., Davis, M., and Buckley, B. M. 1987. Drugs as probes of organ function: Evaluation of the hepatobiliary axis using oral rifampicin and novel high performance liquid chromatography. Ann. Clin. Biochem. 24:36-40.
4. CDC. 1996. CDC Revises HIV Infection Estimates. HIV/AIDS Prevention August:2.
5. Collins, F. M. 1998. Mycobacterial pathogenesis: a historical perspective. Frontiers in Biosci. 3:123-132.
6. Firsov, A. A., Umnova, L. V., Stepanov, V. M., and Fomina, I. P. 1986. Modelling of rifampicin pharmacokinetics in experimental animals administered the drug intravenously and intenally. Antiobiot. Med. Biotekhnol. 31:445-449.
7. Gilding, D. K., and Reed, A. M. 1979. Biodegradable polymers for use in surgery polyglycolic/poly(lactic acid) homo- and copolymers. Polymer 20:1459-1464.
8. Group, Facts and Comparisons Publishing. 1994. Drug Facts and Comparisons. St. Louis: Wolters Kluwer Company.
9. Gurumurthy, P., Ramachandran, G., Vijayalakshmi, S., Kumar, A. K., Venkatesan, P., Chandrasekaran, V., Vjayasekaran, V., Kumaraswami, V., and Prabhakar, R. 1999. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics. Int. J. Tuberc. Lung Dis. 3:119-125.
10. Loos, U., Musch, E., Jensen, J. C., Mikus, G., Schwabe, H. K., and Eichelbaum, M. 1985. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63:1205-1211.
11. Pillai, G., Ellard, G. A., Smith, P. J., and Fourie, P. B. 2001. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations. Int. J. Tuberc. Lung Dis. 5:691-695.
12. Quenelle, D. C., Staas, J. K. Winchester, G. A. Barrow, E. L. W., and Barrow, W. W. 1999. Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice. Antimicrob. Agents Chemother. 43:1144-1151.
13. Quenelle, D. C., Winchester, G. A., Staas, J. K. Barrow, E. L. W., and Barrow, W. W. 2001. Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob. Agents Chemother. 45:1637-1644.
14. Tice, T. R., and Cowsar, D. R. 1984. Biodegradable controlled-release parenteral systems. J. Pharmaceut. Technol. 8:26-35.
15. Visscher, G. E., Robison, R. L., and Argentieri, G. I. 1987. Tissue response to biodegradable injectable microcapsules. J. Biomat. Appl. 2:118-131.
16. Visscher, G. E., Robison, R. L., Maulding, H.V., Fong, J. W., Pearson, J. E., and Argentieri, G. I. 1985. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J. Biomed. Materials Res. 19:349-365.
17. Visscher, G. E., Robison, R. L. Maulding, H. V., Fong, J. W., Pearson, J. E., and Argentieri, G. I. 1986. Biodegradation of and tissue reaction to microcapsules. J. Biomed. Materials Res. 20:667-676.
18. Wolf, R. H., Gibson, S. V., Watson, E. A., and Baskin, G. B. 1988. Multidrug chemotherapy of tuberculosis in rhesus monkeys. Lab. Animal Sci. 38:25-33.
19. Ziia, A. V., Sokolov, G. B., and Firsov. A. A. 1987. Pharmcokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients. Antiobiot. Med. Biotekhnol. 32:223-227.